產(chǎn)品訂購(gòu)信息：
英文名稱(chēng)  Anti-PIM1 

中文名稱(chēng)   絲氨酸/蘇氨酸激酶蛋白Pim1抗體規(guī)格 

別    名  Oncogene PIM 1; Oncogene PIM1; PIM 1; pim 1 kinase 44 kDa isoform; Pim 1 kinase; pim 1 oncogene (proviral integration site 1); Pim 1 oncogene; PIM; PIM1; pim1 kinase 44 kDa isoform; PIM1_HUMAN; Pim2; PIM3; Proto oncogene serine/threonine protein kinase Pim 1; Proto-oncogene serine/threonine-protein kinase Pim-1; Proviral integration site 1; Proviral integration site 2.

濃    度   1mg/1ml

規(guī) 格  0.2ml/200μg

抗體來(lái)源   Rabbit

克隆類(lèi)型   polyclonal

交叉反應(yīng)   Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Rabbit, Sheep, Guinea Pig 

產(chǎn)品類(lèi)型   一抗  

研究領(lǐng)域     免疫學(xué) 信號(hào)轉(zhuǎn)導(dǎo) 細(xì)胞凋亡 轉(zhuǎn)錄調(diào)節(jié)因子 激酶和磷酸酶

蛋白分子量  predicted molecular weight: 45kDa

性    狀   Lyophilized or Liquid

免 疫 原 KLH conjugated synthetic peptide derived from human PIM1 (257-301aa) 

亞    型   IgG

純化方法   affinity purified by Protein A

儲(chǔ) 存 液   0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide

絲氨酸/蘇氨酸激酶蛋白Pim1抗體規(guī)格 產(chǎn)品應(yīng)用    WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復(fù)） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 PIM1 is a member of the serine/threonine kinase PIM oncogene family. PIM1 has been implicated in lymphomagenesis, cell proliferation, apoptosis, differentiation and tumourigenesis. The PIM1 protein kinase is upregulated in prostate cancer.

Function : Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity. The stabilization of MYC exerced by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1. Phosphorylation of MAP3K5, an other proapoptotic protein, by PIM1, significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis. Stimulates cell cycle progression at the G1-S and G2-M transitions by phosphorylation of CDC25A and CDC25C. Phosphorylation of CDKN1A, a regulator of cell cycle progression at G1, results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A protein stability. Promote cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression, CDKN1B, at both transcriptional and post-translational levels. Phosphorylation of CDKN1B,induces 14-3-3-proteins binding, nuclear export and proteasome-dependent degradation. May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3. Acts also as a regulator of homing and migration of bone marrow cells involving functional interaction with the CXCL12-CXCR4 signaling axis.

Subunit : Isoform 2 is isolated as a monomer whereas isoform 1 complexes with other proteins. Binds to RP9. Isoform 1, but not isoform 2, binds BMX. Isoform 2 interacts with CDKN1B and FOXO3. Interacts with BAD. Interacts with PPP2CA; this interaction promotes dephosphorylation of PIM1, ubiquitination and proteasomal degradation. Interacts with HSP90, this interaction stabilizes PIM1 protein levels. Interacts (ubiquitinated form) with HSP70 and promotes its proteosomal degradation. Interacts with CDKN1A. Interacts with CDC25C. Interacts (via N-terminal 96 residues) with CDC25A. Interacts with MAP3K5. Interacts with MYC.

Subcellular Location : Isoform 2: Cytoplasm. Nucleus. Isoform 1: Cell membrane.

Post-translational modifications : Autophosphorylated on both serine/threonine and tyrosine residues. Phosphorylated. Interaction with PPP2CA promotes dephosphorylation.

Ubiquitinated, leading to proteasomal degradation.

Similarity : Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. PIM subfamily.

Contains 1 protein kinase domain.

Database links : UniProtKB/Swiss-Prot: P11309.3

PIM1蛋白是絲氨酸/蘇氨酸蛋白激酶2家族成員，參與細(xì)胞信號(hào)轉(zhuǎn)導(dǎo)、細(xì)胞凋亡、轉(zhuǎn)錄調(diào)節(jié)，在很多中表達(dá)，尤其是，表達(dá)水平較高。

Anti-CD28/FITC 熒光素標(biāo)記CD28蛋白抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Anti-HRG- Alpha/FITC 熒光素標(biāo)記抗HRGα抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh CD99/E2 antigen CD99抗體 規(guī)格 0.2ml

Podoplanin Protein 平足蛋白抗原 0.5mg

IFIT3 英文名稱(chēng)： 干擾素誘導(dǎo)的三角形四肽重復(fù)蛋白3抗體 0.2ml

Rhesus antibody Rh TCF12/HEB 轉(zhuǎn)錄因子12抗體 規(guī)格 0.2ml

Anti-HRG- Alpha/FITC 熒光素標(biāo)記抗HRGα抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Human anti-thrombin receptor,ATR ELISA Kit 人抗凝血酶受體Multi-class antibodies規(guī)格： 48T

Anti-Phospho-S6 Ribosomal Protein (Ser235/236) 磷酸化S6核糖體蛋白抗體Multi-class antibodies規(guī)格： 0.1ml

Rhesus antibody Rh GSK-3 Beta (CT) 葡萄糖合成激酶-3β抗體 規(guī)格 0.1ml

LHRH(Mouse Luteinizing Hormone-Releasing Hormone) ELISA Kit 小鼠黃體生成素釋放激素 96T

OAS1 英文名稱(chēng)： 寡腺苷酸合成酶-1 0.1ml

Bim 英文名稱(chēng)： 細(xì)胞死亡調(diào)解子抗體 0.1ml

Anti-Phospho-S6 Ribosomal Protein (Ser235/236) 磷酸化S6核糖體蛋白抗體Multi-class antibodies規(guī)格： 0.1ml

Human Agrin ELISA Kit 人聚集蛋白Multi-class antibodies規(guī)格： 48T

Anti-SOD2 超氧化物歧化酶2抗體Multi-class antibodies規(guī)格： 0.1ml

Rhesus antibody Rh Goat anti-Mouse IgM whole serum 羊抗小鼠IgM抗血清 規(guī)格 1ml

C4a ELISA Kit 大鼠過(guò)敏毒素/補(bǔ)體片斷4a 96T

phospho-NIFK (Thr234) 英文名稱(chēng)： 磷酸化NIFK抗體 0.1ml

BMP11 英文名稱(chēng)： 骨形態(tài)發(fā)生蛋白11抗體 0.1ml

Anti-SOD2 超氧化物歧化酶2抗體Multi-class antibodies規(guī)格： 0.1ml

CL-0088H4-IIE(大鼠細(xì)胞 )5×106cells/瓶×2

VEGFA Others Human 人 VEGF / VEGFA / VEGF165 桿狀病毒-昆蟲(chóng)細(xì)胞裂解液 (陽(yáng)性對(duì)照)

人脈絡(luò)叢成纖維細(xì)胞裂解物HCPFL

ES-2細(xì)胞，人卵巢透明細(xì)胞癌細(xì)胞 人腎上腺皮質(zhì)腺癌細(xì)胞,NCI-295R細(xì)胞 腎成纖維細(xì)胞Many types of cells包裝：5 × 105次方(1ml)

家兔皮膚細(xì)胞;DR-S1

SLIK1 Others Human 人 SLIK1 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)

CL-0087H4(人)5×106cells/瓶×2

IgG2 Others Human 人 IgG2-Fc (257 Ser/Ala) 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)

小鼠直腸平滑肌細(xì)胞完全培養(yǎng)基 100mL

SV40 MES 13小鼠腎小球系膜細(xì)胞 SV40 MES 13 in mouse glomerular mesangial cells DMEM培養(yǎng)基+5%FBS

CF Protein Rat 重組大鼠 CF / Ciliary Neuroophic Factor 蛋白

SC-1(小鼠胚胎細(xì)胞) 5×106cells/瓶×2 K562(慢性髓原)

絲氨酸/蘇氨酸激酶蛋白Pim1抗體規(guī)格 CADM3 Others Rat 大鼠 CADM3 / NECL1 / IGSF4B 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)

CL-0395NCI-H2227(人小細(xì)胞細(xì)胞)5×106cells/瓶×2

小鼠肺平滑肌細(xì)胞完全培養(yǎng)基 100mL

NIH/3T3小鼠胚胎細(xì)胞 NIH/3T3 mouse embryo cells DMEM+10% FBS

IL36B Protein Human 重組人 IL36B / IL1F8 蛋白 (His 標(biāo)簽)

NCI-H2170(人肺鱗癌細(xì)胞) 5×106cells/瓶×2 HT-29(細(xì)胞)

抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn)：

1. 絲氨酸/蘇氨酸激酶蛋白Pim1抗體規(guī)格 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會(huì)抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對(duì) 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；

2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會(huì)有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來(lái)篩選最適條件；

3.用NHSB量過(guò)量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；

4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等；

5.當(dāng)游離ε-氨基(賴(lài)氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會(huì)降低或損傷抗體蛋白的結(jié)合力或活性；

6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價(jià)結(jié)合；

7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會(huì)對(duì)生物素化抗體與親和素的結(jié)合產(chǎn)生競(jìng)爭(zhēng)作用；

8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對(duì)某些細(xì)胞可導(dǎo)致高本底。

抗體的鑒定：

1）絲氨酸/蘇氨酸激酶蛋白Pim1抗體規(guī)格 抗體的效價(jià)鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來(lái)鑒定。

2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識(shí)別能力?？贵w的特異性高,它的識(shí)別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來(lái)表示。交叉反應(yīng)率可用競(jìng)爭(zhēng)抑制試驗(yàn)測(cè)定。以不同濃度抗原和近似抗原分別做競(jìng)爭(zhēng)抑制曲線,計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。 

如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無(wú)窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。

3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫(kù)侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol。抗體親和力的測(cè)定對(duì)抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。